Kvaliteta života povezana sa zdravljem u bolesnika s primarnim glaukomom otvorenog kuta by Irena Sesar et al.
Acta Clin Croat 2020; 59:623-631 Original Scientific Paper
doi: 10.20471/acc.2020.59.04.08
Acta Clin Croat, Vol. 59, No. 4, 2020  623
HEALTH-RELATED QUALITY OF LIFE  
IN PRIMARY OPEN-ANGLE GLAUCOMA PATIENTS
Irena Sesar1, Anita Pušić Sesar1, Darija Jurišić1, Antonio Sesar1,  
Ivan Merdžo1 and Ivan Ćavar1,2
1Department of Ophthalmology, Mostar University Hospital, Mostar, Bosnia and Herzegovina;  
2Department of Physiology, School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina
SUMMARY – The purpose of this research was to evaluate the relationship between general 
health-related quality of life (GHRQL) and sociodemographic factors in primary open-angle glau-
coma (POAG) patients. A prospective cross-sectional study included 207 glaucoma patients. GHRQL 
was determined via two self-administered questionnaires: the 36-Item Short Form Survey (SF-36) 
and the EuroQol-5D (EQ-5D) questionnaire. Male and 50- to 69-year-old glaucoma patients, fol-
lowed by patients who regularly used antiglaucoma therapy and those without progression of glauco-
ma reported a significantly higher quality of life as measured by the EQ-5D index and the EQ-5D 
visual analog scale (VAS) (p<0.05 all). Similarly, the Physical Component Summary (PCS) and Men-
tal Component Summary (MCS) of SF-36 had significantly higher values for these patients (p<0.05 
all). Furthermore, glaucoma patients with higher education and economic status, glaucoma patients 
who lived in rural areas, and those who were married achieved higher scores on EQ-5D and SF-36. 
In conclusion, progression of the disease, female sex, older age, lower education and economic status, 
urban area and unmarried status negatively affect quality of life in glaucoma patients.
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Introduction
Glaucoma with a prevalence of around 2% in per-
sons older than 40 years is the second most common 
cause of blindness worldwide. It has a significant im-
pact on the economy and healthcare system due to the 
increased treatment expenses and incidence of disabil-
ity1-3. It is estimated that primary open-angle glauco-
ma (POAG) as the most common form of the disease 
will affect approximately 80 million individuals by 
2020 and over 110 million people by 20404,5. Since 
glaucoma can influence general health-related quality 
of life (GHRQL) and vision-related quality of life 
(VRQL) via mode of treatment and as a result of vi-
sual impairment, determination of the general health 
status and visual status of these patients can be of great 
significance6,7. A combination of sociodemographic in-
dicators, clinical examination and questionnaires that 
measure quality of life enables clinicians to better esti-
mate the influence of glaucoma seriousness on the pa-
tient quality of life. This can help achieve better patient 
education and compliance, as well as helping select 
optimal treatment8. Loss of vision negatively affects 
the patient quality of life and psychosocial status, and 
vice versa, patients with lower psychosocial status and 
poorer quality of life show poorer outcomes of glau-
coma treatment. Despite the significant progress 
achieved in recent years, insufficient compliance of pa-
tients with respect to their physicians or prescribed 
therapies is a significant limiting factor in the treat-
ment of glaucoma9-12. There are many difficulties re-
garding patient compliance, such as long-term treat-
ment, environmental factors, difficulties in drug use, 
forgetfulness, lack of discipline, lack of understanding 
that glaucoma is a serious illness, poor communication 
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with the doctor, high prices and side effects of ocular 
medicines, etc.13-15. Thus, improvements in communi-
cation between patients and ophthalmologists and 
better understanding of the nature of POAG may con-
siderably increase regularity of taking antiglaucoma 
medications16,17.
Surveys conducted in India and Spain showed that 
poorer economic status, lower education level, female 
sex and older age contributed directly to poorer quality 
of life in glaucoma patients18,19. Buys et al. and Jones et 
al. showed that socioeconomic deprivation and visual 
field (VF) worsening were associated with greater se-
verity of glaucoma at presentation and a decline in 
VRQL20,21. It has been shown that quality of life is 
negatively associated with the frequency of depression 
and anxiety, especially in female and unmarried pa-
tients with POAG22. Labiris et al. showed that urban 
residence was associated with a tendency towards ben-
eficial effects on the ‘Distant activities’ and ‘Social 
functioning’ subscales of the vision-specific quality of 
life measure23. To our knowledge, no published data are 
available regarding the impact of glaucoma on the 
quality of life of people living in Bosnia and Herze-
govina.
Considering the above-mentioned issues, our re-
search was conducted with the aim of determining the 
relationship between subjective estimation of the 
health condition of POAG patients and disease pro-
gression and sociodemographic factors.
Patients and Methods
Patients
A prospective, cross-sectional study was conducted 
at the Department of Ophthalmology, Mostar Univer-
sity Hospital, Mostar, Bosnia and Herzegovina, be-
tween June 2018 and June 2020. A total of 207 patients 
with POAG were included in the study. The inclusion 
criteria were as follows: diagnosis of POAG (increased 
intraocular pressure (>21 mm Hg), typical glaucoma-
tous defects in VF, optic disk lesions and open angle of 
anterior chamber), patients over 50 years of age, exis-
tence of glaucomatous defects in VF up to 12 dB (mean 
defect (MD) <12 dB) and cataract up to C2NC2P2 
level, since higher opacity in the lens significantly de-
creased visual acuity and contributed to VF defects. Pa-
tients were excluded from the study if they presented 
any of the following: surgical and/or laser procedures 
on an eye, all types of glaucoma except for POAG, cat-
aract of higher level than C2NC2P2, corneal and reti-
nal pathology that significantly reduced visual acuity, 
and advanced stage of glaucoma (MD >12 dB). Pa-
tients who met the inclusion criteria were interviewed 
and gave written informed consent prior to participa-
tion in the study. All procedures and examinations were 
approved by the Ethics Committee of the Mostar Uni-
versity Hospital. The study was conducted in compli-
ance with the Declaration of Helsinki.
Clinical evaluation
All participants underwent a standard ophthal-
mologic examination that included uncorrected and 
best-corrected visual acuity, applanation tonometry, 
pachymetry, gonioscopy, slit lamp inspection, and di-
lated fundus examination. VF defects were detected by 
static perimetry with an Octopus 900 PRO device 
(Haag-Streit, Koeniz, Switzerland) using G TOP/
White/White standard program. Images were ana-
lyzed using the MD and pattern standard deviation 
(PSD) parameters of VF defects. Measurements of 
cup-disk ratio and peripapillary retinal nerve fiber lay-
er (RNFL) thickness were performed using a Cirrus 
spectral-domain, high-definition optical coherence to-
mography device (OCT, Carl Zeiss Meditec Inc., 
Dublin, CA, USA). The patients included in the re-
search were invited for follow-up examinations at 6, 12 
and 18 months after initial ophthalmologic examina-
tion. Every check-up included complete ophthalmo-
logic examination, VF recording and OCT of the op-
tic nerve, and peripapillary RNFL. After final follow-
up examination at 18 months, patients were divided 
into two groups of patients with and without POAG 
progression according to the criteria for glaucoma pro-
gression established by Hodapp et al.24.
Instruments used on data collection
All respondents filled out three questionnaires, i.e. 
general questionnaire on sociodemographic data (sex, 
age, educational level, personal income, place of resi-
dence and marital status) and two questionnaires mea-
suring GHRQL: the 36-Item Short Form Survey 
(SF-36) and the EuroQol-5D (EQ-5D) question-
naire. SF-36 is a set of generic, coherent and easily ad-
ministered quality of life measures which rely upon 
patient self-reporting and are now widely utilized for 
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routine monitoring and assessment of care outcomes 
in adult patients. It is a short form survey of the Med-
ical Outcomes Study, consisting of 36 questions. After 
completing this questionnaire, an eight-domain profile 
of functional health and benefit scores, as well as sum-
marized measures of physical and mental health and a 
usefulness index based on health priorities, were cre-
ated. Each domain included between 2 and 10 ques-
tions and each question had between 2 and 6 possible 
answers. The domains of physical functioning, restric-
tions due to physical health, bodily pain and general 
health created a summary scale measuring the Physical 
Component Summary (PCS), while the domains of 
vitality, social functioning, restrictions due to emotion-
al problems and mental health created a summary 
scale measuring the Mental Component Summary 
(MCS).
The EQ-5D is a generic multidimensional ques-
tionnaire composed of two parts: the EQ-5D descrip-
tive system (index) and the EQ-5D visual analog scale 
(EQ-5D VAS). Five dimensions were considered: mo-
bility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. Each dimension has three levels: 
no problems, some problems, and severe problems. 
Each answer was converted to a single-digit number 
and the digits for each dimension were combined into 
a five-digit number describing the patient health state. 
This five-digit number was then elaborated using a 
unified scoring algorithm. The EQ-VAS cards mea-
sured self-reported general health status using a verti-
cal thermometer-analog scale where the endpoints are 
labeled ‘best imaginable health state’ and ‘worst imag-
inable health state’.
With regard to the level of education, the respon-
dents were divided into two groups by applying the 
International Standard Classification of Education 
(ISCED) 2011, the standard framework used to cate-
gorize and report cross-nationally comparable educa-
tion statistics. Patients categorized as ‘lower education’ 
were those who had ISCED level 0 – early childhood 
education, ISCED level 1 – primary education and 
ISCED level 2 – lower secondary education. Patients 
categorized as ‘higher education’ were those who had 
ISCED level 3 – upper secondary education, ISCED 
level 4 – post-secondary non-tertiary education and 
ISCED levels 5-8, which describe various levels of ter-
tiary (academic) education. The average personal an-
nual income in Bosnia and Herzegovina for the years 
2018 and 2019 was approximately 8,860.00 BAM 
(~5,000.00 USD).
Statistical analysis
Descriptive statistical methods were used for de-
scription of the frequency distribution for all variables 
analyzed. Continuous variables were expressed as 
mean ± standard deviation, while the values of cate-
gorical variables were expressed as N (%). Student’s 
t-test was used to compare continuous variables be-
tween groups. Logistic regression analysis was used to 
determine predictors of glaucoma progression. The 
odds ratios, confidence intervals and levels of signifi-
cance were examined to evaluate the individual predic-
tor variables. The level of statistical significance was set 
at p<0.05. Analyses were carried out using SPSS soft-
ware version 20.0 (SPSS Inc., Chicago, IL, USA).
Results
A total of 207 respondents met the criteria for in-
clusion in the study, of which 80 (38.6%) were men 
and 127 (61.4%) were women. The mean age of pa-
tients with POAG was 68.52±9.10 years, ranging from 
50 to 89 years. The SF-36 and EQ-5D instruments 
were used, where a higher score indicated higher qual-
ity of life for all described domains/scales of SF-36 
and EQ-5D questionnaires.
Table 1 shows the EQ-5D-determined quality of 
life for patients with POAG with respect to sex, age, 
regularity of using antiglaucoma eyedrops, progression 
of disease, education level, economic status, area of liv-
ing and marital status. From these results, it is clear 
that male and patients aged 50-69 years had a signifi-
cantly higher quality of life, followed by patients who 
regularly used antiglaucoma therapy and those with-
out progression of glaucoma, as measured by the EQ-
5D index and EQ-5D VAS (p<0.05 all). Furthermore, 
glaucoma patients with a higher educational level and 
economic status, patients who lived in rural areas and 
those who were married achieved higher scores on 
EQ-5D. The difference was statistically significant for 
‘Personal income’ as measured by the EQ-5D index 
(p=0.003) and EQ-5D VAS (p=0.001).
Table 2 shows the SF-36-determined quality of life 
for patients with POAG with respect to sex, age, regu-
larity of using antiglaucoma eyedrops, progression of 
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Table 1. Quality of life in patients with POAG measured with EQ-5D
Variable n EQ-5D index t-test p EQ-5D VAS t-test p
Sex    
 Male 80 0.57±0.28 2.237 0.026 60.88±17.27 2.750 0.006
 Female 127 0.50±0.27 56.04±16.60
Age (yrs)     
 50-69 104 0.57±0.27 3.357 0.001 61.44±16.87 4.711 0.001
 ≥70 103 0.47±0.26 53.78±16.17
Topical AG therapy     
 Regular 141 0.54±0,27 2.797 0.005 58.91±16.54 3.405 0.001
 Non-regular 66 0.44±0.26 51.52±17.65
Progression of disease    
 Yes 63 0.45±0.15 3.625 <0.001 53.56±18.16 2.989 0.002
 No 144 0.60±0.28 60.47±13.68
Education     
 Lower qualification 135 0.52±0.22 1.220 0.223 57.36±16.48 0.796 0.130
 Higher qualification 72 0.57±0.27 60.00±20.71
Personal income     
 <5,000 USD 107 0.48±0.26 2.966 0.003 54.67±16.23 3.772 0.001
 ≥5,000 USD 100 0.56±0.25 60.80±17.17
Area     
 Urban 130 0.51±0.25 1.390 0.165 57.00±17.00 1.631 0.104
 Rural 77 0.56±0.26 60.54±16.54
Marital status     
 Married 124 0.54±0.27 1.349 0.178 59.51±17.90 1.582 0.112
 Unmarried 83 0.50±0.27 56.81±15.04
POAG = primary open-angle glaucoma; EQ-5D = EuroQol-5D; n = number of patients; VAS = visual analog scale; 
AG = antiglaucoma
disease, education level, economic status, area of living 
and marital status. The PCS and MCS scales of SF-36 
showed significantly higher scores in male and pa-
tients aged 50-69 years than in patients who regularly 
used antiglaucoma therapy and those without progres-
sion of glaucoma (p<0.05 all). Furthermore, glaucoma 
patients with a higher educational level and economic 
status, patients who lived in rural areas and those who 
were married achieved higher scores on the PCS and 
MCS scales of SF-36. Statistical significance was 
achieved for ‘Area’ on the MCS scale (p=0.004) and for 
‘Marital status’ on the MCS scale (p=0.003).
Predictive factors for glaucoma progression are 
shown in Table 3. Considering all domains/scales of 
EQ-5D and SF-36, as well as all sociodemographic 
factors, the ‘Social functioning’ domain of SF-36 was 
found to be the only significant predictive factor for 
progression of POAG (OR=0.953; p<0.001).
Discussion
Glaucoma influences daily living both through vi-
sual impairment and as a result of the glaucoma treat-
ment itself. Quality of life is a measure that is hard for 
medical experts to quantify but is very important for 
patients. In glaucoma patients, it is necessary to be fa-
miliar with perceptions of personal health and dis-
abilities in everyday activities6,12. Since glaucoma does 
not only affect vision-related daily functions, we used 
the SF-36 and EQ-5D questionnaires in our research, 
as these are the most commonly used instruments for 
the assessment of GHRQL6,7.
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Table 2. Quality of life in patients with POAG measured with SF-36
Variable  n SF-36 PCS t-test p SF-36 MCS t-test p
Sex
 Male 80 40.96±9.65 2.968 0.003 42.79±10.69 2.979 0.003
 Female 127 38.04±8.81 39.59±9.49
Age (yrs)
 50-69 104 39.97±8.11 3.243 0.002 41.74±9.13 3.586 <0.001
 ≥70 103 35.75±8.43 36.12±8.72
Topical AG therapy
 Regular 141 39.62±9.20 3.142 0.002 41.43±9.90 3.658 <0.001
 Non-regular 66 35.79±8.37 36.61±9.47
Progression of disease
 Yes 63 36.59±9.29 3.415 0.001 38.22±10.12 3.146 0.002
 No 144 39.99±8.95 41.64±9.77
Education
 Lower qualification 135 38.77±9.00 1.103 0.276 39.86±12.17 0.406 0.287
 Higher qualification 72  40.74±10.60 40.68±9.73
Personal income
 <5,000 USD 107 38.05±8.40 1.127 0.225 40.09±9.46 1.043 0.298
 ≥5,000 USD 100 39.91±9.84 41.14±10.50
Area
 Urban 130 38.90±9.25 0.263 0.293 39.98±10.15 2.908 0.004
 Rural 77 39.22±8.87  43.39±8.71
Marital status
 Married 124 39.38±9.93 1.119 0.264 41.86±9.74 2.993 0.003
 Unmarried 83 38.37±7.96 38.82±10.08
POAG = primary open-angle glaucoma; SF-36 = 36-Item Short Form Survey; n = number of patients; PCS = Physical Com-
ponent Summary; MCS = Mental Component Summary; AG = antiglaucoma
The results of our study showed that male patients 
with POAG had a significantly higher quality of life 
than female patients with POAG. These results mostly 
correlate with the results of numerous studies under-
taken worldwide19,23. The data can be interpreted as 
indicating that females in the general population have 
a slightly poorer quality of life than males in all age 
groups. In addition, respondents aged 50-69 years had 
a significantly higher quality of life than patients older 
than 70 years. This finding was confirmed by other 
studies, as well as by the fact that age has been nega-
tively correlated with quality of life in the general pop-
ulation25,26.
Patients who regularly used antiglaucoma therapy 
achieved significantly higher scores on the EQ-5D 
and SF-36 questionnaires. The results of studies in 
France, China, USA and Brazil showed that the main 
factors influencing poor compliance between doctors 
and patients and irregular use of antiglaucoma drugs 
were insufficient information given to patients about 
the nature of glaucoma disease, problems in under-
standing and in communication with a doctor, prob-
lems with application of the eyedrops, and high prices 
and side effects of ocular medicines13-l5,27. All these fac-
tors essentially disrupt the quality of life in glaucoma 
patients, and therefore improvement in communica-
tion between physicians and patients, as well as im-
proved patient knowledge about the course of the dis-
ease may significantly increase the regularity of taking 
antiglaucoma medicines16,17. Furthermore, develop-
ment of new antiglaucoma eyedrops (such as analogs 
of prostaglandins and fixed combinations) that de-
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crease the number of drippings per day could certainly 
contribute to better patient compliance with the ad-
vice of ophthalmologists. However, the problem of the 
high price of new medicines still remains28.
Our results revealed that patients with glaucoma 
progression had a significantly lower level of physical 
and mental health than patients without disease dete-
rioration. In 2005, Lin and Yang conducted a cross-
sectional research among 280 glaucoma patients using 
SF-36 and the National Eye Institute Visual Func-
tioning Questionnaire-25 (NEIVFQ-25). The scores 
obtained by these questionnaires showed that progres-
sion of glaucoma negatively correlated with quality of 
life8. Wilson et al. also report that worsening of glau-
coma is a strong predictor of lower SF-36 scores29. Ac-
cording to literature data, the association between VF 
loss and deterioration of VRQL is largely linear. This 
means that VRQL declines at a constant rate as the 
VF worsens30,31. In fact, Jones et al. report that the as-
sociation between VRQL decline and VF worsening is 
more likely to be described as monotonic. In other 
words, the relationship could have both slow and rapid 
stages, or even remain relatively constant for a time21. 
Some studies showed better correlation between VF 
worsening and VRQL decline obtained by using vi-
sion-specific questionnaires such as NEIVFQ-25, 
Glaucoma Quality of Life-15 (GQL-15) and Visual 
Function Index (VF-14). This can be explained by the 
assumption that specific questionnaires for eye diseas-
es correlate more strongly with early VF changes in 
comparison to instruments that measure GHRQL7,32,33.
The results of this research showed that glaucoma 
patients with a higher educational level and economic 
status achieved higher scores as measured by the EQ-
5D index and EQ-5D VAS, as well as by the PSC and 
MCS scales of the SF-36 instrument. The results of 
other studies confirm that educational level is an im-
portant factor that significantly influences and posi-
tively correlates with quality of life23,25,34,35. Kharicha et 
al. report that lower educational status and aging sig-
nificantly contribute to poorer patient compliance 
with physicians’ advice, and therefore negatively influ-
ence quality of life36. Most studies have shown positive 
correlation between socioeconomic status and quality 
of life in glaucoma patients16,23,25,34. Low socioeconom-
ic status is associated with late diagnosis and more se-
vere POAG at presentation. Indeed, socioeconomi-
cally deprived groups have demonstrated a higher 
need for information on the practical aspects of 
POAG, such as ocular medication usage, social sup-
port for visually-impaired individuals, irreversibility of 
optic nerve damage, and seriousness of glaucoma exis-
tence within the family37. Patients with higher levels of 
education and higher incomes are in better position to 
use modern and more expensive antiglaucoma medi-
cations, and show a tendency to do so34.
Our results showed that patients with POAG who 
lived in rural areas achieved higher scores in EQ-5D 
and SF-36. A significant difference was observed only 
for the MCS scale. Vijaya et al. report a higher preva-
lence of POAG in urban population compared to rural 
Table 3. Predictive factors for glaucoma progression
Variable Odds ratio df p
Mobility 3.670 1 0.055
Self-care 0.147 1 0.702
Usual activities 0.389 1 0.533
Pain/discomfort 0.211 1 0.646
Anxiety/depression 1.337 1 0.248
EQ-5D index 3.276 1 0.070
EQ-5D visual analog scale 1.120 1 0.290
Physical functioning 0.201 1 0.654
Restrictions due to physical 
health 0.029 1 0.865
Bodily pain 0.789 1 0.374
General health 0.065 1 0.799
Vitality 0.228 1 0.633
Social functioning 0.953 1 <0.001
Restrictions due to 
emotional problems 0.118 1 0.731
Mental health 0.029 1 0.864
Physical Component 
Summary 0.352 1 0.553
Mental Component 
Summary 0.001 1 0.975
Sex 3.162 1 0.075
Age 3.235 1 0.072
Education level 0.604 1 0.437
Personal income 0.044 1 0.834
Area 0.889 1 0.346
Marital status 1.172 1 0.279
Overall statistics 16.198 23 0.843
EQ-5D = EuroQol-5D
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population, which could be caused by the possible influ-
ence of lifestyle differences and a higher prevalence of 
systemic diseases such as hypertension and diabetes in 
the urban population38. This could explain the relatively 
higher quality of life of people living in rural areas. Con-
trary to our results, Labiris et al. report higher values for 
some aspects of VRQL in urban populations23. We 
showed that glaucoma patients who were married 
scored higher on the EQ-5D and SF-36 instruments in 
comparison to unmarried patients with POAG. It was 
shown that older people living alone were more likely to 
report poor health, poor vision, difficulties with instru-
mental and basic activities of daily living, worse memory 
and mood, lower physical activity, risk of social isolation, 
etc36. All these factors may contribute significantly to 
poorer GHRQL. In 2005, a study conducted in Japan 
on 600 men and 2,587 women aged >65 showed that 
health status positively correlated with visual function, 
physical mobility, lack of depression and social integra-
tion39. Studies have shown that bilateral VF defects and 
depressive symptoms were more prevalent in glaucoma 
patients with impaired VRQL40,41. It was found that vi-
sual function and ganglion cell-inner plexiform layer 
thickness were decreased in depressive patients42. Fur-
thermore, Jayawant et al. found the presence of depres-
sive symptoms to negatively affect the regularity of tak-
ing antiglaucoma therapy and to increase the cost of 
glaucoma treatment43.
In conclusion, progression of the disease and pre-
disposing sociodemographic factors such as female sex, 
older age, lower education and economic status, urban 
area and unmarried status negatively affect quality of 
life in glaucoma patients.
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Sažetak
KVALITETA ŽIVOTA POVEZANA SA ZDRAVLJEM  
U BOLESNIKA S PRIMARNIM GLAUKOMOM OTVORENOG KUTA
I. Sesar, A. Pušić Sesar, D. Jurišić, A. Sesar, I. Merdžo i I. Ćavar
Svrha ovoga istraživanja bila je utvrditi odnos između kvalitete života povezane s općim zdravljem (GHRQL) i sociode-
mografskih čimbenika u bolesnika s primarnim glaukomom otvorenog kuta (POAG). Riječ je o presječnoj studiji u kojoj je 
sudjelovalo 207 bolesnika s POAG. GHRQL mjerena je pomoću dva upitnika: kratkog upitnika zdravstvenog statusa s 36 
pitanja (SF-36) i upitnika EuroQol-5D (EQ-5D). Muškarci i bolesnici s glaukomom u dobi od 50-69 godina, zatim bole-
snici koji su redovito koristili antiglaukomsku terapiju i oni bez progresije glaukoma izvijestili su o znatno višoj kvaliteti 
 života mjerenoj indeksom EQ-5D i vizualnom analognom ljestvicom EQ-5D (VAS) (p<0,05 za sve usporedbe). Slično 
tome, Sažetak fizičkih komponenata (PCS) i Sažetak mentalnih komponenata (MCS) upitnika SF-36 imali su značajno veće 
vrijednosti za ove bolesnike (p<0,05 za sve usporedbe). Nadalje, ispitanici s visokim stupnjem obrazovanja i ekonomskim 
statusom, ispitanici koji žive u ruralnim područjima i oni koji su u braku postigli su veće rezultate na EQ-5D i SF-36. 
 Zaključno, napredovanje bolesti, ženski spol, starija životna dob, niži stupanj obrazovanja i ekonomski status, urbano po-
dručje življenja i samoća negativno utječu na kvalitetu života bolesnika s glaukomom.
Ključne riječi: Glaukom; Kvaliteta života povezana sa zdravljem; Sociodemografski čimbenici
